TGFβ/activin signaling pathway activation in intimal hyperplasia and atherosclerosis

Diagnostic and Interventional Radiology

Volumn 17, Issue 3, 2011, Pages 290-296

  Öklü, Rahmi ^a   Hesketh, Robin ^b   Wicky, Stephan ^a   Metcalfe, James ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; Coronary artery disease; Immunohistochemistry; Vascular intima

Indexed keywords

ACTIVIN; LATENCY ASSOCIATED PEPTIDE; LATENCY ASSOCIATED PEPTIDE 1; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AORTA; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CELL DENSITY; CONTROLLED STUDY; CORONARY ARTERY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; NEOINTIMA; PROTEIN EXPRESSION;

ACTIVINS; AORTA, THORACIC; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY VESSELS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TISSUE EMBEDDING; TRANSFORMING GROWTH FACTOR BETA1; TUNICA INTIMA;

EID: 80052047864     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.4261/1305-3825.DIR.3844-10.1     Document Type: Article

References (33)

1. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1360-1369.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97:2099-2100.
4. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
7. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34:631-638.
8. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96:4095-4103.
9. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89:2462-2478.
10. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95:1062-1071.
11. Raines EW, Ross R. Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? Bioessays 1996; 18:271-282.
12. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor- BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994; 93:1266-1274.
13. Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J 1992; 11:4251-4259.
14. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791.
15. Printseva O, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. Am J Pathol 1992; 140:889-896.
16. Shimizu Y, Newman W, Gopal TV, et al. Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM- 1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 1991; 113:1203-1212.
17. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355-1374.
18. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000; 342:101-114.
19. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule- 1 on endothelial cells. Circulation 1998; 98:1164-1171.
20. Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc 1995; 70:571-596.
21. Grainger DJ, Metcalfe JC, Grace AA, Mosedale DE. Transforming growth factor- beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci 1998; 111 (Pt 19):2977-2988.
22. Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000; 113 (Pt 13):2355-2361.
23. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67:753-791.
24. Bobik A, Agrotis A, Kanellakis P, et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 1999; 99:2883-2891.
25. Ihling C, Technau K, Gross V, Schulte- Monting J, Zeiher AM, Schaefer HE. Concordant upregulation of type II-TGFbeta- receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis 1999; 144:7-14.
26. McCaffrey TA, Du B, Fu C, et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999; 31:1627-1642.
27. Grainger DJ, Mosedale DE, Metcalfe JC. TGFbeta in blood: a complex problem. Cytokine Growth Factor Rev 2000; 11:133-145.
28. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999; 59:2731-2738.
29. Werner M, Von Wasielewski R, Komminoth P. Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem Cell Biol 1996; 105:253-260.
30. Oklu R, Hesketh R, Wicky S. Localization of latent transforming growth factor-β binding protein-1 (LTBP1) in human coronary atherosclerotic plaques. Paper presented at 2010 Arterioscler Thromb Vasc Biol Conference; Abstract P376; April 8, 2010; San Francisco, USA.
31. Engelse MA, Neele JM, van Achterberg TA et al. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 1999; 85:931-939.
32. Oklu R, Hesketh R, Wicky S. Expression of latent transforming growth factor-β binding protein-1 (LTBP1) isoforms coronary atherosclerosis. Paper presented at 2010 Arterioscler Thromb Vasc Biol Conference; Abstract P171; April 8, 2010; San Francisco, USA.
33. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460-462.